The company we keep: Why physicians should refuse to see pharmaceutical representatives

Howard Brody

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will ad contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counter-argument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.

Original languageEnglish (US)
Pages (from-to)82-85
Number of pages4
JournalAnnals of Family Medicine
Volume3
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Physicians
Time Management
Pharmaceutical Preparations
Ethical Analysis
Research

Keywords

  • Drug industry
  • Ethics
  • Health care delivery
  • Health services research

ASJC Scopus subject areas

  • Family Practice

Cite this

The company we keep : Why physicians should refuse to see pharmaceutical representatives. / Brody, Howard.

In: Annals of Family Medicine, Vol. 3, No. 1, 01.2005, p. 82-85.

Research output: Contribution to journalArticle

@article{e80f956127a1477aaa3708c457622b33,
title = "The company we keep: Why physicians should refuse to see pharmaceutical representatives",
abstract = "Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will ad contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counter-argument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.",
keywords = "Drug industry, Ethics, Health care delivery, Health services research",
author = "Howard Brody",
year = "2005",
month = "1",
doi = "10.1370/afm.259",
language = "English (US)",
volume = "3",
pages = "82--85",
journal = "Annals of Family Medicine",
issn = "1544-1709",
publisher = "Annals of Family Medicine, Inc",
number = "1",

}

TY - JOUR

T1 - The company we keep

T2 - Why physicians should refuse to see pharmaceutical representatives

AU - Brody, Howard

PY - 2005/1

Y1 - 2005/1

N2 - Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will ad contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counter-argument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.

AB - Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will ad contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counter-argument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.

KW - Drug industry

KW - Ethics

KW - Health care delivery

KW - Health services research

UR - http://www.scopus.com/inward/record.url?scp=13444263830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444263830&partnerID=8YFLogxK

U2 - 10.1370/afm.259

DO - 10.1370/afm.259

M3 - Article

C2 - 15671196

AN - SCOPUS:13444263830

VL - 3

SP - 82

EP - 85

JO - Annals of Family Medicine

JF - Annals of Family Medicine

SN - 1544-1709

IS - 1

ER -